Skip to Content

Generic Velphoro Availability

Velphoro is a brand name of sucroferric oxyhydroxide, approved by the FDA in the following formulation(s):

VELPHORO (sucroferric oxyhydroxide - tablet, chewable;oral)

  • Manufacturer: VIFOR FRESENIUS
    Approval date: November 27, 2013
    Strength(s): 500MG [RLD]

Has a generic version of Velphoro been approved?

No. There is currently no therapeutically equivalent version of Velphoro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Velphoro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
    Patent 6,174,442
    Issued: January 16, 2001
    Inventor(s): Geisser; Peter & Philipp; Erik
    Assignee(s): Vifor (International) AG

    An adsorbent for phosphate from aqueous medium, particularly for inorganic phosphate or phosphate bound to foodstuffs from body fluids or foodstuffs, which contains beta-iron hydroxide stabilized by carbohydrates and/or by humic acid.

    Patent expiration dates:

    • December 19, 2018
      Drug substance
  • Pharmaceutical compositions
    Patent 9,561,251
    Issued: February 7, 2017
    Assignee(s): Vifor Fresenius Medical Care Renal Pharma Ltd.

    Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

    Patent expiration dates:

    • January 23, 2030
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.